These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 25365558

  • 1. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L, Han G, Gu B, Yin H.
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [Abstract] [Full Text] [Related]

  • 2. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [Abstract] [Full Text] [Related]

  • 3. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H, Lu Q, Wood M.
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M, Tanganyika-de Winter C, Bosgra S, Aartsma-Rus A.
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, Silva O, Wang RT, Martinez L, Lu QL, Damoiseaux R, Spencer MJ, Nelson SF, Miceli MC.
    Sci Transl Med; 2012 Dec 12; 4(164):164ra160. PubMed ID: 23241744
    [Abstract] [Full Text] [Related]

  • 8. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.
    Mol Ther; 2017 Nov 01; 25(11):2561-2572. PubMed ID: 28865998
    [Abstract] [Full Text] [Related]

  • 9. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
    Williams JH, Sirsi SR, Latta DR, Lutz GJ.
    Mol Ther; 2006 Jul 01; 14(1):88-96. PubMed ID: 16488666
    [Abstract] [Full Text] [Related]

  • 10. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    J Gene Med; 2009 Mar 01; 11(3):257-66. PubMed ID: 19140108
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R, Yokota T.
    Methods Mol Biol; 2021 Mar 01; 2224():203-214. PubMed ID: 33606217
    [Abstract] [Full Text] [Related]

  • 13. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
    Yin H, Saleh AF, Betts C, Camelliti P, Seow Y, Ashraf S, Arzumanov A, Hammond S, Merritt T, Gait MJ, Wood MJ.
    Mol Ther; 2011 Jul 01; 19(7):1295-303. PubMed ID: 21505427
    [Abstract] [Full Text] [Related]

  • 14. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S, Mizobe Y, Takizawa H, Hara Y, Yokota T, Takeda S, Aoki Y.
    Methods Mol Biol; 2018 Jul 01; 1687():123-141. PubMed ID: 29067660
    [Abstract] [Full Text] [Related]

  • 15. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG, 't Hoen PAC, Diaz Parillas V, Tanganyika-de Winter CL, Verheul RC, Aguilera B, de Visser PC, Aartsma-Rus AM.
    Mol Ther; 2018 Jan 03; 26(1):132-147. PubMed ID: 29103911
    [Abstract] [Full Text] [Related]

  • 16. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M, Spitali P, Datson N, Aartsma-Rus A.
    Methods Mol Biol; 2018 Jan 03; 1828():249-262. PubMed ID: 30171546
    [Abstract] [Full Text] [Related]

  • 17. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    Ann N Y Acad Sci; 2009 Sep 03; 1175():71-9. PubMed ID: 19796079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.